Estimated reading time: 14 minutes
Table of contents
- Overview
- What Dual-Use Conversion Is
- The $10 Million Fee and Payment Options
- The May 1, 2027 Timeline
- Strategic Considerations for Incumbents
- How to Prepare Now
- Work With Catalyst BC on Your Dual-Use Conversion Strategy
- Success Stories: See How Catalyst BC Has Helped Cannabis Businesses Enter and Lead the Market
- Virginia Dual-Use Cannabis Conversion FAQs
- Additional Resources
- Free eBooks For Cannabis Business Success
- Latest Articles
Editor’s Notes: This article is part of our Virginia 2027 Licensing Hub. Other topics covered in this series are:
- Virginia Cannabis License 2027 Application Guide
- How to Open a Dispensary in Virginia
- Virginia Cannabis Microbusiness License Guide
- Virginia Cannabis Cultivation License Guide
- Virginia Impact Cannabis License Guide
- Virginia Cannabis Facility Design and Build-Out
- Virginia Dual-Use Cannabis Conversion Guide
Overview
For Virginia’s existing medical cannabis operators, the 2026 retail framework created a distinct and high-stakes transition: pharmaceutical processors may apply for verification to exercise dual-use privileges and serve both registered medical patients and adult-use customers. The pathway covers the processor and its permitted cannabis dispensing facilities, and it carries a one-time $10 million fee, a required medical cannabis program preservation plan, an impact-licensee business accelerator commitment, and a firm May 1, 2027 payment or installment-plan deadline. Adult-use retail sales begin July 1, 2027. For incumbents, this is not merely an optional expansion decision: a processor that does not apply for dual-use verification and pay the fee in full or enter an approved installment plan by May 1 may not renew its permit, and previously issued permits do not remain valid after June 1, 2027 without dual-use verification. This guide explains the pathway, the operating conditions, and the financial and facility planning required to prepare.
This is necessarily a focused, operator-facing topic – it applies to Virginia’s permitted pharmaceutical processors and their affiliated cannabis dispensing facilities rather than the general public. For those companies, however, the decision is enormous because dual-use verification affects market access, medical-program continuity, facility capacity, ownership strategy, and the ability to renew the underlying permit.
What Dual-Use Conversion Is
Under Virginia’s framework, a permitted pharmaceutical processor must apply to the Virginia Cannabis Control Authority Board (CCA) for verification to exercise dual-use privileges. This is more precise than a simple license conversion. Once verified, the pharmaceutical processor holds the privileges of, and is generally subject to the laws and regulations applicable to, a marijuana cultivation facility, marijuana processing facility, and retail marijuana store. Its permitted cannabis dispensing facilities receive retail marijuana store privileges. The operator must continue satisfying its medical-cannabis obligations while also complying with the adult-use requirements applicable to those activities.
| Element | Detail |
| Who it applies to | Permitted Virginia pharmaceutical processors; verified privileges also extend to their permitted cannabis dispensing facilities |
| What it grants | The processor receives adult-use cultivation, processing, and retail privileges; its dispensing facilities receive adult-use retail privileges while medical operations continue |
| Application requirements | CCA must create a streamlined process by February 1, 2027; the processor must apply as directed and obtain approval of a detailed medical cannabis program preservation plan |
| Conversion fee and deadline | One-time $10 million fee, paid in full or placed under a Board-approved installment plan on or before May 1, 2027 |
| Additional commitment | Agreement to participate in an impact-licensee business accelerator plan for at least three years after verification |
| Permit and launch timeline | A processor that does not complete the required application and payment step may not renew its permit; previously issued permits require verification to remain valid after June 1, 2027; adult-use retail begins July 1, 2027 |
The $10 Million Fee and Payment Options
The statutory requirement is a one-time $10 million conversion fee. A pharmaceutical processor may either pay the fee in full by May 1, 2027 or enter, by that date, an installment payment plan approved by the CCA Board. The law does not specify the installment term, down payment, interest treatment, or security requirements; those details will depend on the Board’s approved plan and implementing guidance. Operators should therefore model the full $10 million obligation alongside facility expansion, inventory, staffing, technology, compliance, and working-capital needs rather than assuming the installment option materially reduces the total cost. The separate statutory provision directing 75% of certain annual marijuana-establishment license fees to the Cannabis Equity Business Loan Fund does not expressly apply to the $10 million conversion fee.
Expert Insight – Model verification as an investment and continuity decision, not just a fee. The $10 million obligation is the price of adult-use access, but the analysis cannot stop at projected new revenue. A processor also has to preserve medical-patient access, satisfy the accelerator commitment, scale facilities and compliance systems, and maintain the underlying permit. For a well-positioned incumbent, the opportunity may be compelling. For an operator with limited capacity or weak execution, the fee can magnify existing problems. The decision deserves rigorous financial, operational, and regulatory modeling.
Leif Olsen – Catalyst BC Chief Executive Officer
The May 1, 2027 Timeline
Timing is tight and consequential. By February 1, 2027, the CCA must create a streamlined application process for pharmaceutical processors, and each processor must apply in the manner and by the date prescribed by the Board. On or before May 1, the processor must satisfy the applicable licensing requirements and either pay the $10 million fee in full or enter an approved installment plan. The CCA must verify eligible processors’ dual-use privileges by that point. Beginning June 1, 2027, a previously issued pharmaceutical processor permit does not remain valid without dual-use verification. Adult-use retail sales begin July 1, 2027.
The application is not simply a payment election. Each processor must submit and obtain approval of a detailed medical cannabis program preservation plan explaining how it will prioritize patient access, manage customer traffic, prevent medical-product shortages, and maintain appropriate staffing. The processor must also agree to participate in an impact-licensee business accelerator plan for at least three years after verification. These requirements should be treated as core operating commitments, not paperwork completed at the end of the process.
Strategic Considerations for Incumbents
If you’re an existing Virginia pharmaceutical processor, the dual-use verification decision turns on several questions I’d work through carefully:
- Medical-program preservation and capacity. Can your current cultivation, processing, inventory, and dispensing capacity support adult-use demand without reducing product access or service quality for medical patients? Your preservation plan must address traffic flow, supply shortages, and staffing in concrete operational terms.
- Facility readiness. Are your cultivation, processing, and dispensing facilities capable of handling dual-use throughput, security, inventory segregation, customer flow, and regulatory reporting? Existing facilities operating by the statutory cutoff receive certain location and retail-floor exemptions, but future modifications remain subject to CCA review and other applicable requirements.
- Financial structure. Does full payment or an approved installment plan better fit your capital position, and how does the $10 million obligation compare with projected adult-use revenue, expansion costs, carrying costs, and working-capital needs? Do not model an installment structure until the Board’s actual terms are known.
- Ownership, licensing, and accelerator obligations. The law restricts a person holding at least a 10% ownership, voting, or economic interest in a pharmaceutical processor from holding an interest in another marijuana-establishment license, except the processor’s permitted dispensing facilities. The processor must also commit to at least three years of participation in an impact-licensee business accelerator plan.
- Competitive timing and compliance scope. Verification gives incumbents a meaningful infrastructure advantage, but adult-use retail may not begin before July 1, 2027. Once verified, processors and dispensing facilities become subject to the adult-use requirements associated with their new cultivation, processing, and retail privileges while continuing to meet medical-program obligations.
Expert Insight – Dual-use verification is a medical-continuity and operations decision as much as a financial one. The $10 million fee gets the attention, but the preservation plan and operating model will determine whether the transition works. Adult-use volume cannot come at the expense of patient access. Treat verification as an integrated readiness exercise: establish the medical-demand baseline, model adult-use demand, validate cultivation and processing capacity, plan inventory and customer flow, scale staffing and compliance, and commission any facility changes before launch. The fee buys access to the market; disciplined execution determines whether the head start becomes a lasting advantage.
Michael Williamson – Catalyst BC Chief Operating Officer
How to Prepare Now
For pharmaceutical processors preparing for dual-use verification, the runway to May 1, 2027 should be used to:
- Prepare the application and medical cannabis program preservation plan with specific patient-access, traffic-flow, shortage-prevention, and staffing procedures.
- Model the full financial obligation including the $10 million fee, possible installment terms, facility upgrades, staffing, compliance, inventory, and working capital through launch.
- Validate capacity and facility readiness across cultivation, processing, storage, dispensing, security, technology, and customer throughput while maintaining medical supply.
- Complete an ownership and regulatory gap analysis addressing the 10% cross-ownership restriction, adult-use operating requirements, medical-program obligations, and any required facility approvals.
- Prepare for the three-year accelerator commitment and monitor the CCA for the streamlined application, approved installment-plan terms, verification procedures, and implementing regulations.
Work With Catalyst BC on Your Dual-Use Conversion Strategy
For Virginia’s incumbent pharmaceutical processors, dual-use verification is a defining strategic and continuity decision – a $10 million obligation tied to adult-use market access, permit renewal, patient-access protections, and a major operational expansion. At Catalyst BC, we help established operators evaluate and execute this transition by modeling facility and production capacity, assessing dispensary throughput and customer flow, developing operational inputs for the required medical cannabis program preservation plan, identifying compliance and ownership gaps, planning capital projects, and aligning cultivation, processing, dispensing, staffing, and commissioning work to the July 1, 2027 launch. We coordinate this operational planning with qualified legal and financial advisors responsible for interpreting the governing requirements and structuring the payment and ownership arrangements. Contact our team to build a dual-use readiness plan that protects the medical program while preparing the business for adult-use demand.
About the authors: This guide was prepared by the Catalyst BC cannabis consulting team. Catalyst BC advises cannabis operators on state licensing strategy, market entry and expansion, capacity and facility planning, regulatory compliance, and cannabis facility design and commissioning across U.S. and international markets. This article is provided for informational purposes only and does not constitute legal or financial advice; operators should confirm current dual-use conversion requirements with the Virginia Cannabis Control Authority and consult qualified counsel and financial advisors regarding their specific circumstances.
Success Stories: See How Catalyst BC Has Helped Cannabis Businesses Enter and Lead the Market
From initial startup and facility build-outs to high-value exit strategies, our cannabis consultants provide the expertise needed to navigate the complexities of the legal cannabis industry.
Virginia Dual-Use Cannabis Conversion FAQs
Virginia law describes this as verification to exercise dual-use privileges. A permitted pharmaceutical processor that applies, satisfies the requirements, and pays the $10 million fee or enters an approved installment plan may exercise adult-use cultivation, processing, and retail privileges. Its permitted cannabis dispensing facilities may exercise adult-use retail privileges, while the medical program continues.
The one-time conversion fee is $10 million per pharmaceutical processor. It must be paid in full, or the processor must enter a CCA Board-approved installment plan, on or before May 1, 2027.
The pathway applies to pharmaceutical processors holding permits under Virginia’s medical cannabis program. Their permitted cannabis dispensing facilities receive dual-use retail privileges through the processor’s verification; this is not a pathway for new general applicants.
The CCA must create a streamlined process by February 1, 2027. Each processor must apply as directed and, by May 1, pay the fee in full or enter an approved installment plan. A processor that does not complete those steps may not exercise dual-use privileges or renew its permit, and previously issued permits require verification to remain valid after June 1, 2027. Adult-use retail begins July 1, 2027.
It is a detailed plan that must be submitted to and approved by the CCA. It must explain how the processor will prioritize medical-patient access, manage customer traffic, prevent medical-product shortages, and maintain appropriate staffing while adding adult-use operations.
A pharmaceutical processor must agree to participate in an impact-licensee business accelerator plan for at least three years after dual-use verification. The Cannabis Impact Business Support Team and CCA will define the applicable program requirements.
Yes. The processor may enter an installment payment plan approved by the CCA Board on or before May 1, 2027. The statute does not establish the detailed payment term, interest treatment, security, or other conditions, so operators should wait for the Board’s published terms before relying on a particular structure.
The processor must add adult-use volume without undermining medical access. Key challenges include cultivation and processing capacity, inventory planning, product availability, retail traffic, staffing, security, seed-to-sale tracking, facility throughput, compliance, and commissioning any expansions before launch.
Yes. A person holding at least a 10% direct or indirect ownership, voting, or economic interest in a pharmaceutical processor generally may not hold an interest in another marijuana-establishment license, except the cannabis dispensing facility permits associated with the processor. Operators should have qualified counsel review ownership and affiliate structures.
The statutory pathway, $10 million fee, preservation-plan requirement, accelerator commitment, and major deadlines are enacted. The CCA still must publish the streamlined application, installment-plan terms, verification procedures, and implementing regulations. Pharmaceutical processors should plan against the enacted requirements while monitoring CCA guidance closely.
Additional Resources
Free eBooks For Cannabis Business Success
Latest Articles
- Virginia Cannabis Cultivation License (2027): The Tiered System Explained
For operators whose strength is growing cannabis, Virginia’s emerging adult-use market presents a significant opportunity – and a cultivation license is the gateway to it. The June 2026 framework authorizes the Virginia Cannabis Control Authority (CCA) to begin accepting license applications on or after February 1, 2027 and issuing licenses on or after May 1, 2027. It also establishes five cultivation tiers with maximum canopies ranging from 5,000 to 35,000 square feet. - Virginia Impact Cannabis License (2027): Social Equity & the Equity Business Loan Fund
Virginia’s adult-use cannabis framework creates a meaningful pathway for applicants from communities and backgrounds affected by cannabis prohibition and enforcement. The law does not create a separate, stand-alone impact license. Instead, it creates an impact-licensee designation that qualifying applicants may pursue alongside an underlying marijuana establishment license, such as retail, cultivation, processing, microbusiness, transportation, delivery, or testing. - Virginia Cannabis Microbusiness License (2027): Eligibility & the Two-Location Model
This guide explains the initial eligibility pathways for the licenses the CCA may issue by May 1, 2027, the difference between a microbusiness license and an impact designation, the indoor and outdoor cultivation limits, the precise rules governing two locations, and the financial, security, and operational readiness standards applicants should prepare to demonstrate. Several implementation details – including fees and the specific combination of privileges the CCA will authorize – still depend on forthcoming regulations. - Virginia Dual-Use Cannabis Conversion (2027): The $10M Medical-to-Adult-Use Pathway
For Virginia’s existing medical cannabis operators, the 2026 retail framework created a distinct and high-stakes transition: pharmaceutical processors may apply for verification to exercise dual-use privileges and serve both registered medical patients and adult-use customers. The pathway covers the processor and its permitted cannabis dispensing facilities, and it carries a one-time $10 million fee, a required medical cannabis program preservation plan, an impact-licensee business accelerator commitment, and a firm May 1, 2027 payment or installment-plan deadline. - Virginia Cannabis Facility Design & Build-Out for the 2027 Market
This guide covers the major considerations involved in planning and building a Virginia cannabis facility, with a focus on retail and cultivation operations and additional considerations relevant to processors and microbusinesses. It is written from the build side of the business, because that is where many otherwise-strong applicants stumble: they underestimate utility needs, local approvals, security infrastructure, commissioning, and the time required to convert a site into an inspection-ready operation. - How to Open a Dispensary in Virginia: The 2027 Retail Store License Guide
If you’ve been waiting for the chance to open a cannabis dispensary in Virginia, that chance is now real. With the General Assembly’s June 2026 approval of a regulated retail framework, Virginia is on track to begin adult-use sales on July 1, 2027, and the Cannabis Control Authority (CCA) is expected to open license applications on February 1, 2027.